Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTE NASDAQ:LABP NASDAQ:NLTX NASDAQ:SBTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTEAerovate Therapeutics$6.88-8.6%$8.63$56.35▼$105.00$199.42M0.9512,438 shs146,854 shsLABPLandos Biopharma$22.93+0.6%$22.54$2.50▼$22.94$71.77M0.1419,700 shs50,800 shsNLTXNeoleukin Therapeutics$21.68-4.6%$19.81$2.03▼$14.36$203.75M1.1150,104 shs78,279 shsSBTXSilverback Therapeutics$17.88+0.7%$16.23$2.80▼$8.97$644.72M0.6337,931 shs1.11 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTEAerovate Therapeutics0.00%-13.70%-15.67%-18.42%-87.83%LABPLandos Biopharma0.00%0.00%0.00%0.00%0.00%NLTXNeoleukin Therapeutics0.00%-2.95%+34.16%+44.53%-44.58%SBTXSilverback Therapeutics-3.27%+0.91%-2.47%+27.06%+61.95%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVTEAerovate TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ALABPLandos BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTEAerovate Therapeutics 0.00N/AN/AN/ALABPLandos Biopharma 0.00N/AN/AN/ANLTXNeoleukin Therapeutics 0.00N/AN/AN/ASBTXSilverback Therapeutics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTEAerovate TherapeuticsN/AN/AN/AN/A$3.96 per shareN/ALABPLandos Biopharma$18M3.99N/AN/A$7.41 per share3.09NLTXNeoleukin TherapeuticsN/AN/AN/AN/A$11.08 per shareN/ASBTXSilverback TherapeuticsN/AN/AN/AN/A$7.41 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTEAerovate Therapeutics-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%8/11/2025 (Estimated)LABPLandos Biopharma-$21.93M-$3.99N/AN/AN/AN/A-73.00%-63.00%N/ANLTXNeoleukin Therapeutics-$57.56M-$3.11N/A∞N/AN/A-37.22%-30.91%N/ASBTXSilverback Therapeutics-$89.48M-$2.42N/A∞N/AN/A-29.62%-28.20%N/ALatest LABP, AVTE, SBTX, and NLTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025AVTEAerovate Therapeutics-$0.25N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVTEAerovate TherapeuticsN/AN/AN/AN/AN/ALABPLandos BiopharmaN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTEAerovate TherapeuticsN/A8.788.78LABPLandos BiopharmaN/A4.434.43NLTXNeoleukin TherapeuticsN/A15.3315.33SBTXSilverback TherapeuticsN/A67.8767.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTEAerovate TherapeuticsN/ALABPLandos Biopharma49.06%NLTXNeoleukin Therapeutics52.37%SBTXSilverback Therapeutics74.89%Insider OwnershipCompanyInsider OwnershipAVTEAerovate Therapeutics24.90%LABPLandos Biopharma1.30%NLTXNeoleukin Therapeutics1.58%SBTXSilverback Therapeutics34.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTEAerovate Therapeutics2028.99 million21.69 millionOptionableLABPLandos Biopharma193.13 million3.09 millionNot OptionableNLTXNeoleukin Therapeutics909.40 million9.25 millionNo DataSBTXSilverback Therapeutics8336.06 million23.65 millionNot OptionableLABP, AVTE, SBTX, and NLTX HeadlinesRecent News About These CompaniesSilverback Therapeutics (NASDAQ:SBTX) Shares Down 1.9% - Should You Sell?July 17, 2025 | marketbeat.comMeet the Silverback, the Leader of the TroopOctober 17, 2024 | pbs.orgP10 Fun Facts About Mountain GorillasSeptember 18, 2024 | nationalgeographic.comNCapstanTx secures $165 million to deliver precise in vivo cell engineeringJuly 28, 2024 | pharmaphorum.comPARS Pharmaceuticals Inc (SPRY)May 11, 2023 | uk.investing.comWild IslesMarch 12, 2023 | wwf.org.ukWA look back at RNA Therapeutics – day oneFebruary 23, 2023 | pharmaphorum.comPSPRY ARS Pharmaceuticals, Inc.January 24, 2023 | seekingalpha.comARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After MergerNovember 22, 2022 | 247wallst.comDr. Sarina Tanimoto Discloses Position in SBTX / Silverback TherapeuticsNovember 18, 2022 | nasdaq.comARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including AnaphylaxisNovember 10, 2022 | finance.yahoo.comARS Pharmaceuticals Closes Merger with Silverback TherapeuticsNovember 8, 2022 | finance.yahoo.comSilverback : FDA Accepts ARS Pharm's NDA For Neffy For Treatment Of Allergic ReactionsOctober 28, 2022 | markets.businessinsider.comFDA accepts ARS Pharma’s NDA for NeffyOctober 24, 2022 | thepharmaletter.comTSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HIL, SBTX, COWN, AERIOctober 23, 2022 | kentuckytoday.comKSilverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including AnaphylaxisOctober 21, 2022 | finance.yahoo.comIs Silverback Therapeutics Inc (SBTX) Stock a Good Investment?October 19, 2022 | aaii.comASHAREHOLDER ALERT: The M&A Class Action Firm is Investigating the Merger – RFP, SBTX, AAWW, COWNOctober 12, 2022 | bakersfield.comBINVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBTSeptember 17, 2022 | markets.businessinsider.comSBTX Silverback Therapeutics, Inc.September 15, 2022 | seekingalpha.comSHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FTAI, SBTX, CVET, GBTSeptember 6, 2022 | markets.businessinsider.comMedia Sentiment Over TimeLABP, AVTE, SBTX, and NLTX Company DescriptionsAerovate Therapeutics NASDAQ:AVTE$6.88 -0.65 (-8.63%) As of 07/30/2025Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Landos Biopharma NASDAQ:LABPLandos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that is in Phase 2 clinical trial to treat ulcerative colitis (UC) and completed Phase 1 to treat Crohn's disease (CD). The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist for the treatment of asthma and eosinophilic disorders; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and neurodegenerative disorders; and LABP-69, an oral PLXDC2 agonist for the treatment of rheumatoid arthritis, UC, and CD. The company has a license and collaboration agreement with LianBio Respiratory Limited to develop, manufacture, and commercialize omilancor and NX-13. Landos Biopharma, Inc. was incorporated in 2017 and is headquartered in Blacksburg, Virginia.Neoleukin Therapeutics NASDAQ:NLTX$21.68 -1.04 (-4.58%) As of 07/28/2025Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.Silverback Therapeutics NASDAQ:SBTX$17.88 +0.13 (+0.73%) As of 07/30/2025Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Blasts Past Earnings—What’s Next for MSFT? Meta Blasts Up 11% on Q2 Results—The AI Train Keeps Chugging Broadcom Tops $300: What's Fueling Gains and a Key Risk to Watch How Marvell Went From Short Target to Breakout Star Visa Beats Q3 Earnings Expectations, So Why Did the Market Panic? Palo Alto Networks: The All‑in‑One Cybersecurity Powerhouse Spotify's Q2 Earnings Plunge: An Opportunity or Ominous Signal? This Drone Stock Is on Sale Despite Big Army Contract Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
